[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100380386":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":31,"locations":40,"responsibleParty":197,"collaborators":30,"id":199,"slug":200,"hasResults":201,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":201,"sex":207,"minAge":208,"maxAge":209,"enrollmentInfo":210,"targetDuration":30,"studyType":213,"phases":214,"briefSummary":216,"conditions":217,"keywords":30,"overallStatus":43,"whyStopped":30,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":228},{"fullName":5,"class":6},"Labo'Life","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"2LPAPI® arm","EXPERIMENTAL","The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule\u002Fday.",[13],"Drug: 2LPAPI®",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo arm","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","2LPAPI®","Treatment",[9],[26],"2LPAPI",{"type":21,"name":28,"description":28,"armGroupLabels":29,"otherNames":30},"Placebo",[15],null,[32,37],{"name":33,"role":34,"phone":35,"phoneExt":30,"email":36},"Laura FERTE","CONTACT","+32499717964","laura.ferte@labolife.com",{"name":38,"role":34,"phone":30,"phoneExt":30,"email":39},"Charlotte BOLLE","charlotte.bolle@labolife.com",[41,66,83,97,110,120,129,141,145,154,166,180],{"facility":42,"status":43,"city":44,"state":30,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"CHU Saint-Pierre","RECRUITING","Brussels","1000","Belgium","BE",{"type":49,"coordinates":50},"Point",[51,52],4.34878,50.85045,{"lat":52,"lon":51},[55,57,59,62,64],{"name":56,"role":34,"phone":30,"phoneExt":30,"email":30},"Yannick Manigart, Dr",{"name":56,"role":58,"phone":30,"phoneExt":30,"email":30},"PRINCIPAL_INVESTIGATOR",{"name":60,"role":61,"phone":30,"phoneExt":30,"email":30},"Aurélie Joris, Dr","SUB_INVESTIGATOR",{"name":63,"role":61,"phone":30,"phoneExt":30,"email":30},"Christine Gilles, Dr",{"name":65,"role":61,"phone":30,"phoneExt":30,"email":30},"Charlotte Rousseau, Dr",{"facility":67,"status":43,"city":44,"state":30,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":68,"geoPoint":70,"contacts":71},"Clinique St Jean",{"type":49,"coordinates":69},[51,52],{"lat":52,"lon":51},[72,74,76,78,80,82],{"name":73,"role":34,"phone":30,"phoneExt":30,"email":30},"Nathanaël DUBOIS",{"name":75,"role":61,"phone":30,"phoneExt":30,"email":30},"Jean-Paul VAN GOSSUM",{"name":77,"role":61,"phone":30,"phoneExt":30,"email":30},"Justine JEHOTTE",{"name":79,"role":61,"phone":30,"phoneExt":30,"email":30},"Andrea RADULESCU",{"name":81,"role":61,"phone":30,"phoneExt":30,"email":30},"Mathilde BARREIRA",{"name":73,"role":58,"phone":30,"phoneExt":30,"email":30},{"facility":84,"status":43,"city":44,"state":30,"zip":85,"country":46,"countryCode":47,"cosmosGeoPoint":86,"geoPoint":88,"contacts":89},"CHU Brugmann","1020",{"type":49,"coordinates":87},[51,52],{"lat":52,"lon":51},[90,92,94,96],{"name":91,"role":34,"phone":30,"phoneExt":30,"email":30},"Tatiana Besse-Hammer, MD",{"name":93,"role":58,"phone":30,"phoneExt":30,"email":30},"Catherine Van Pachterbeke, MD",{"name":95,"role":61,"phone":30,"phoneExt":30,"email":30},"Elie Finianos, MD",{"name":91,"role":61,"phone":30,"phoneExt":30,"email":30},{"facility":98,"status":43,"city":44,"state":30,"zip":99,"country":46,"countryCode":47,"cosmosGeoPoint":100,"geoPoint":102,"contacts":103},"Hôpitaux Iris Sud - Iris Zuid Ziekenhuis","1050",{"type":49,"coordinates":101},[51,52],{"lat":52,"lon":51},[104,106,108],{"name":105,"role":34,"phone":30,"phoneExt":30,"email":30},"Frédéric BUXANT, MD",{"name":107,"role":58,"phone":30,"phoneExt":30,"email":30},"Frédéric Buxant, MD",{"name":109,"role":61,"phone":30,"phoneExt":30,"email":30},"Fiona Avau, MD",{"facility":111,"status":112,"city":113,"state":30,"zip":114,"country":46,"countryCode":47,"cosmosGeoPoint":115,"geoPoint":119,"contacts":30},"Hôpital Civil Marie Curie ISPPC","ACTIVE_NOT_RECRUITING","Charleroi","6042",{"type":49,"coordinates":116},[117,118],4.44448,50.41136,{"lat":118,"lon":117},{"facility":121,"status":112,"city":122,"state":30,"zip":123,"country":46,"countryCode":47,"cosmosGeoPoint":124,"geoPoint":128,"contacts":30},"Centre Hospital Reine Astrid Malmedy (CHRAM)","Malmedy","4960",{"type":49,"coordinates":125},[126,127],6.02794,50.42686,{"lat":127,"lon":126},{"facility":46,"status":43,"city":130,"state":30,"zip":131,"country":46,"countryCode":47,"cosmosGeoPoint":132,"geoPoint":136,"contacts":137},"Namur","5000",{"type":49,"coordinates":133},[134,135],4.86746,50.4669,{"lat":135,"lon":134},[138,140],{"name":139,"role":34,"phone":30,"phoneExt":30,"email":30},"Sarah MITRI",{"name":139,"role":58,"phone":30,"phoneExt":30,"email":30},{"facility":46,"status":112,"city":130,"state":30,"zip":131,"country":46,"countryCode":47,"cosmosGeoPoint":142,"geoPoint":144,"contacts":30},{"type":49,"coordinates":143},[134,135],{"lat":135,"lon":134},{"facility":146,"status":43,"city":130,"state":30,"zip":131,"country":46,"countryCode":47,"cosmosGeoPoint":147,"geoPoint":149,"contacts":150},"Cabinet privé",{"type":49,"coordinates":148},[134,135],{"lat":135,"lon":134},[151,153],{"name":152,"role":34,"phone":30,"phoneExt":30,"email":30},"Benoit MOONS",{"name":152,"role":58,"phone":30,"phoneExt":30,"email":30},{"facility":155,"status":43,"city":130,"state":30,"zip":30,"country":46,"countryCode":47,"cosmosGeoPoint":156,"geoPoint":158,"contacts":159},"UCL Namur - site Sainte Elisabeth",{"type":49,"coordinates":157},[134,135],{"lat":135,"lon":134},[160,162,164,165],{"name":152,"role":34,"phone":30,"phoneExt":30,"email":161},"benoit.moons@chuuclnamur.uclouvain.be",{"name":163,"role":34,"phone":30,"phoneExt":30,"email":30},"MD",{"name":152,"role":58,"phone":30,"phoneExt":30,"email":30},{"name":139,"role":61,"phone":30,"phoneExt":30,"email":30},{"facility":167,"status":168,"city":169,"state":30,"zip":170,"country":46,"countryCode":47,"cosmosGeoPoint":171,"geoPoint":175,"contacts":176},"Clinique Saint-Pierre Ottignies (CSPO)","NOT_YET_RECRUITING","Ottignies","1340",{"type":49,"coordinates":172},[173,174],4.56679,50.66535,{"lat":174,"lon":173},[177,179],{"name":178,"role":34,"phone":30,"phoneExt":30,"email":30},"Lucie Verreth, Dr",{"name":178,"role":58,"phone":30,"phoneExt":30,"email":30},{"facility":181,"status":43,"city":182,"state":30,"zip":183,"country":46,"countryCode":47,"cosmosGeoPoint":184,"geoPoint":188,"contacts":189},"CHWAPI","Tournai","7000",{"type":49,"coordinates":185},[186,187],3.38932,50.60715,{"lat":187,"lon":186},[190,192,194,196],{"name":191,"role":34,"phone":30,"phoneExt":30,"email":30},"Marc WAYEMBERGH, MD",{"name":193,"role":61,"phone":30,"phoneExt":30,"email":30},"Céline PETIT, MD",{"name":195,"role":61,"phone":30,"phoneExt":30,"email":30},"Sandra TASSART, MD",{"name":191,"role":58,"phone":30,"phoneExt":30,"email":30},{"type":198,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100380386","phase-4-study-of-2lpapi-on-the-clearance-of-genital-hr-hpv-infections-100380386",false,"NCT04232917","Study of 2LPAPI® on the Clearance of Genital HR-HPV Infections.","Randomized, Placebo-controlled, Double-blind Study to Evaluate 2LPAPI® Efficacy on the Clearance of Genital HR-HPV Infections.","PAPION","Inclusion Criteria:\n\n* Women 25-45 years,\n* Women of childbearing age under effective contraception,\n* Patient with last cytology less than 3 years and normal or not more than LSIL or CIN I at the histology,\n* Patient with current cytology presenting normal, ASC-US, AGUS, LSIL, ASC-H, AGC or LSIL+ASC-H results or current diagnosis of CIN I at the histology,\n* Patient with HR-HPV diagnosis at the current cervical collection,\n* Patient reporting a current stable sexual relationship (steady sexual partner during study duration),\n* Patient having faculties to understand and respect the constraints of the study,\n* Signature of the Informed Consent Form.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding woman,\n* Patient presenting HSIL diagnosis at the cytology or CIN II or CIN III diagnosis at the histology,\n* Patient having received HPV vaccination in the last month,\n* Patient previously subject to total hysterectomy,\n* Patient under immunotherapy (including immunosuppressive treatment) or micro-immunotherapy received during last previous 6 months,\n* Patient with known lactose intolerance,\n* Patient who participated in a clinical study in the previous 3-months' period,\n* Patient who is not sufficiently motivated to engage in a follow-up period of 12 months, or likely to travel or to move before the end of the study,\n* Patient with severe immunodeficiency disease requiring long term treatment (\\*) or under chemotherapy or radiotherapy,\n* Patient under listed homeopathic or phytotherapy treatment (see protocol),\n* Patient using or addicted to recreational drugs.\n\n(\\*) important renal or respiratory insufficiency, transplanted or grafted patients, HIV\u002FAIDS, terminal cancer.","FEMALE","25 Years","45 Years",{"count":211,"type":212},284,"ESTIMATED","INTERVENTIONAL",[215],"PHASE4","Human papillomavirus (HPV) is a prevalent pathogen, the epidemiology of which has mostly been studied in the uterine cervix and the vagina.\n\nThe KCE Report 238Cs (2015) recommends \" HR-HPV-positive women should not be offered colposcopy immediately. Triage should be done using cytology for this purpose. If cytological abnormalities (ASCUS+) are found, immediate referral should follow for diagnosis and, where appropriate, treatment. If no abnormalities are observed in triage, the subject should be offered follow-up testing (cytology) at six months. \".\n\nThere is no treatment that is recommended during this lap time. The 2LPAPI® has been available for more than 20 years, and has received a marketing authorization in Belgium by the FAMHP. It is used as an immune regulator in the treatment of HR-HPV infections. Since 2LPAPI® has been made available, clinical observational data collected on treated patients have shown the beneficial effect on the clearance of HPV.\n\nThe purpose of this placebo-controlled trial is to evaluate the efficacy of 2LPAPI® on the clearance of genital HR-HPV infections.",[218],"Human Papilloma Virus","2024-10-29",{"date":221,"type":222},"2024-10-31","ACTUAL",{"date":224,"type":222},"2020-10-17",{"date":226,"type":212},"2027-10-30",{"name":5,"class":6},12]